SCHOTT Pharma AG & Co. KGaA : Strong increase in high value solutions support profitable mid-term growth
>Solid set of 2022-23 headline figures at the upper end of guided sales range - Schott Pharma has published headline figures for the financial year 2022-23. Sales amounted to € 899m (+9%), at the upper end of the guided range of € 880-900m and above our estimates of € 883m and the consensus (€ 893m). EBITDA at € 239m (+9%) was slightly below our expectations (€ 244m) but above the consensus of € 236m. The company did not provide a guidance for 2022-23 EBITDA. The figu...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.